Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

SWEF announces further impairment on Irish office loan portfolio

(Sharecast News) - Starwood European Real Estate Finance announced a further impairment on its Irish office loan portfolio on Friday, citing continued pressure in the Dublin office market and uncertainty over recovery prospects. The loan, which represented 7.8% of the company's net asset value as of 31 May, was written down by an additional €7.3m, reducing its carrying value to €6.75m.

That followed an earlier €12.9m impairment booked in October 2024, which had already halved the loan's value at the time.

The latest provision equated to a further 4.2p per share reduction in net asset value.

SWEF said its board had reviewed alternative business plans for the underlying asset and determined that a wide range of outcomes remained possible, with varying levels of potential recovery.

"The investment adviser will continue to actively manage the position to maximise the opportunity for value recovery and the board will continue to closely monitor the position and ongoing developments," Starwood said.

Its net asset value stood at £149.6m as of the end of May, with a net asset value per share of 101.09p.

Starwood said it was currently finalising its second-quarter portfolio update, expected shortly.

Since adopting an orderly wind-down strategy in January 2023, the company had returned £256m to shareholders via compulsory redemptions, equivalent to 61.9% of net asset value as of the strategy's adoption.

At 0950 BST, shares in Starwood European Real Estate Finance were down 1.14% at 87.24p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.